NCT02959476已完成3 期
A Double Blind, Multi-center, Randomized, Placebo-Controlled, Parallel Group, Phase 3 Study to Evaluate the Efficacy and Safety of Ropivacaine 0.2% Pre-Filled Dispenser for the Treatment of Postsurgical Pain in Patients Undergoing Cesarean Delivery
BioQ Pharma, Inc.11 个研究点 分布在 1 个国家目标入组 132 人开始时间: 2017年3月13日最近更新:
适应症
干预措施
相关药物
试验速览
- 阶段
- 3 期
- 状态
- 已完成
- 发起方
- 入组人数
- 132
- 试验地点
- 11
- 主要终点
- Cumulative analgesic effect
研究概览
简要总结
This study evaluates a Ropivacaine 0.2% Pre-Filled Dispenser in the treatment of post-surgical pain in patients undergoing Cesarean delivery. Half of the patients will receive Ropivicaine and half will receive placebo.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
入排标准
- 性别
- Female
- 接受健康志愿者
- 否
入选标准
- •Complete the informed consent process as documented by a signed informed consent form (ICF).
- •Be in generally good health and classified as either PS-1 or PS-2 by the American Society of Anesthetists (ASA) Physical Status Classification System.
- •Have a single birth pregnancy. Can be parous or nulliparous.
- •Be scheduled for a Cesarean Delivery
- •Subjects undergoing emergency Cesarean Delivery will not be eligible for participation in this study.
- •In the event a subject signs the ICF (but has not been randomized), has a C section planned and then has an emergency C section delivery, this subject will be considered a screen failure.
- •In the unlikely event a subject signs the ICF and is randomized into the study, has a C section planned and then has an emergency C section delivery, this subject will continue in the study as planned.
- •Be willing to complete the pain assessments according to the protocol and return to clinic as scheduled, as needed.
排除标准
- •Have an uncontrolled medical condition, serious intercurrent illness, clinically significant general health condition, or extenuating circumstance that may significantly decrease study compliance or otherwise preclude their participation in the study.
- •Have a clinically significant abnormal electrocardiogram (ECG) at screening as determined by the Investigator.
- •Have a history of any medical condition or surgical procedure that would alter the absorption, distribution, metabolism, or excretion of ropivacaine.
- •Have, in the opinion of the investigator, a clinically significant abnormality in their clinical laboratory values (urinalysis, hematology and chemistry) at screening.
- •Have made a donation (standard donation amount or more) of blood or blood products (with the exception of plasma as noted below) within 56 days prior to Day
- •Weigh greater than 100 kg (220 lbs).
- •Have made a plasma donation within 7 days prior to Day -
- •Have a known allergy or hypersensitivity to anesthetics (eg. Ropivacaine), acetaminophen, or non-steroidal anti inflammatory drugs (NSAIDs, eg, ibuprofen or naproxen, ketorolac).
- •Not be able or willing to discontinue the prohibited medications listed below within the allotted time before surgery and throughout the duration of their participation in the study.
- •monoamine oxidase inhibitors (MAOIs) within the past 30 days
- •anticonvulsants, tricyclic antidepressants (TCAs), neuroleptics, serotonin-norepinephrine reuptake inhibitors (SNRIs), as well as selective serotonin reuptake inhibitors (SSRIs) (unless SSRIs have been prescribed for depression and/or anxiety and subjects have been on a stable dose for at least 30 days prior to the screening visit);
- •Corticosteroids: Oral and injectable corticosteroids must be discontinued 3 months prior to surgery; nasal, inhaled and topical corticosteroids will be allowed;
- •Use concurrent therapy that could interfere with the evaluation of efficacy or safety parameters in the opinion of the investigator (eg, any drugs, in the investigator's opinion, that may exert significant analgesic properties), except for rescue medications.
- •Have a history of seizures or history of serious head injury.
- •Must not be a member of a vulnerable population as defined by the Code of Federal Regulations Title 45, Part 46, Delivery 46.111(b), including but not limited to employees (temporary, part-time, full-time, etc.) or a family member of the research staff conducting the study, or of the Sponsor, or of the Clinical Research Organization.
- •Have previously participated in a clinical trial using ropivacaine.
- •Have a history of major mental illness that in the opinion of the Investigator may affect the ability of the subject to participate in the study. Institutionalized subjects will not be eligible for participation.
研究组 & 干预措施
Placebo
Placebo Comparator
Naropin® (ropivacaine HCl Injection, USP) bolus + placebo infusion (normal saline) - "Placebo treatment arm"
干预措施: Placebos (Drug)
Ropivacaine 0.2%
Experimental
Naropin® (ropivacaine HCl Injection, USP) bolus + Ropivacaine 0.2% Pre-Filled Dispenser infusion - "Ropivacaine Infusion treatment arm"
干预措施: Ropivacaine (Drug)
结局指标
主要结局
Cumulative analgesic effect
时间窗: 48 hours
次要结局
- Overall safety using descriptive statistics of the evaluation of physical exam, vital signs, clinical laboratory tests, and treatment-emergent adverse events(7 days)
- Use of other analgesics(48 hours)
- Local safety and tolerability using descriptive statistics of the evaluation of physical exams, wound healing and treatment-emergent adverse events local to the surgical wound(7 days)
- Analgesic effect at specified intervals(48 hours)
研究者
研究点 (11)
Loading locations...
相似试验
撤回
不适用
Comparing the Effect of TAP-catheter and Epidural Catheter on Postoperative Pain After Open Gynecologic SurgeryPain, PostoperativeNCT01760174Aalborg University Hospital
已完成
不适用
A Comparison of Ropivacaine Alone Versus Combination of Dexamethasone and Clonidine for BlockUpper Extremity SurgeryNCT02151487University of Texas Southwestern Medical Center97
Unknown
4 期
Effects of Intra-Operative Ropivaciane Epidural Injection on Post-Operative Outcomes Following Elective Lumbar FusionPain, PostoperativeNCT03035656Horizon Health Network228
已完成
不适用
The effect of Ropivacaine on post-operative pain after Transcataneous Percataneous NepholytotomyPain after Percutaneous Nephrolithotomy.Calculus of kidneyIRCT201307153773N8Tehran University of Medical Sciences60
已完成
3 期
MIRs 04 : Interpectoral Nerve Block With Ropivacaine Versus Placebo Before Breast Cancer SurgeryMalignant Neoplasm of BreastNCT04327063Institut Curie182